AAVogen
Tuesday, June 04, 2024
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 4
AAVogen is a preclinical stage biotech company that develops gene therapeutics for inclusion body myositis, heart failure and other muscle wasting disease states. This includes proprietary liver de-targeted/muscle specific AAV capsids (AVGN6.1, 6.2, 6.3 & 6.4) and AVGN7; a patented gene therapeutic that prevents wasting of skeletal and cardiac muscle. Licensing opportunities are sought for the capsids while AVGN7 is being developed to treat sporadic inclusion body myositis, heart failure and rare muscle/neuromuscular diseases.
Company Website:
https://aavogen.com/
Lead Product in Development:
AVGN7
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Company HQ City
Rockville
Company HQ State
MD
Company HQ Country
United States
CEO/Top Company Official
Buel D. Rodgers, PhD
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())